Vioxx, known generically as Rofecoxib, was a nonsteroidal anti-inflammatory drug (NSAID) used to treat osteoarthritis, acute pain conditions, and dysmenorrhea. It was developed by Merck & Co. and received FDA approval in 1999. Unlike traditional NSAIDs, Vioxx selectively inhibited the cyclooxygenase-2 (COX-2) enzyme, theoretically reducing gastrointestinal side effects.
